Tobacco Use Disorder
Med Clin North Am. 2022 Jan;106(1):99-112. doi: 10.1016/j.mcna.2021.08.011.ABSTRACTTobacco use disorder is highly prevalent; more than a billion individuals use tobacco worldwide. Popular views on the addictive potential of tobacco often underestimate the complex neural adaptations that underpin continued use. Although sometimes trivialized as a minor substance, effects of nicotine on behavior lead to profound morbidity over a lifetime of exposure. Innovations in processing have led to potent forms of tobacco and delivery devices. Proactive treatment strategies focus on pharmacotherapeutic interventions. Innovations on the...
Source: Clinical Lung Cancer - November 26, 2021 Category: Cancer & Oncology Authors: Frank T Leone Sarah Evers-Casey Source Type: research

Bronchial Artery Chemoembolization for Hemoptysis in Advanced Primary Lung Cancer
The objective response rate was 73.8%, and the disease control rate was 87.7%. Median HFS of the 154 clinically successful cases was 10.5 months (95% confidence interval [CI]: 8.11-11.89). The degree of hemoptysis (massive hemoptysis hazard ratio [HR] = 5.9, 95% CI: 3.43-10.16, P = .00) and cavitary lung mass (HR = 2.39, 95% CI: 1.44-3.99, P = .001), were significantly related to a reduction in HFS after BAICE. The 6-month and 12-month survival rates were 66.5% and 45.6%, respectively. The median OS of clinically successful cases was 13.0 months (95% CI: 11.22-14.77). The median OS of 16 clinically failed cases was 2.0 mon...
Source: Clinical Lung Cancer - November 26, 2021 Category: Cancer & Oncology Authors: Li Xiaobing Yin Meipan Xie Pengfei Zhao Yue Liu Ying Li Xiangnan Qi Yu Ma Yaozhen Li Chunxia Wu Gang Source Type: research

Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial
Clin Lung Cancer. 2021 Oct 10:S1525-7304(21)00265-5. doi: 10.1016/j.cllc.2021.09.010. Online ahead of print.ABSTRACTFor patients with resectable, early-stage non-small-cell lung cancer (NSCLC), surgery is the primary treatment; however, 5-year survival rates remain poor. Postoperative adjuvant platinum-doublet chemotherapy is associated with a statistically significant but modest improvement in survival of ∼5% at 5 years and is widely accepted as standard of care in patients with resectable, Stage II-III NSCLC. Neoadjuvant chemotherapy has been associated with similar improvements in overall survival to adjuvant therap...
Source: Clinical Lung Cancer - November 25, 2021 Category: Cancer & Oncology Authors: John V Heymach Tetsuya Mitsudomi David Harpole Mike Aperghis Stephanie Jones Helen Mann Tamer M Fouad Martin Reck Source Type: research

Analysis of urinary VOCs using mass spectrometric methods to diagnose cancer: A review
Clin Mass Spectrom. 2020 Oct 31;18:27-37. doi: 10.1016/j.clinms.2020.10.004. eCollection 2020 Nov.ABSTRACTThe development of non-invasive screening techniques for early cancer detection is one of the greatest scientific challenges of the 21st century. One promising emerging method is the analysis of volatile organic compounds (VOCs). VOCs are low molecular weight substances generated as final products of cellular metabolism and emitted through a variety of biological matrices, such as breath, blood, saliva and urine. Urine stands out for its non-invasive nature, availability in large volumes, and the high concentration of ...
Source: Clinical Lung Cancer - November 25, 2021 Category: Cancer & Oncology Authors: Bruno Ruiz Brand ão da Costa Bruno Spinosa De Martinis Source Type: research

Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations
CONCLUSIONS: EGFR or ALK alterations occur in patients with LUSC, especially never-smoker females. TKI treatments render clinical benefit in disease control, but the duration was considerably truncated compared with those historically observed in LUAD.PMID:34820641 | PMC:PMC8600084 | DOI:10.1016/j.jtocrr.2021.100237 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - November 25, 2021 Category: Cancer & Oncology Authors: Whitney E Lewis Lingzhi Hong Frank E Mott George Simon Carol C Wu Waree Rinsurongkawong J Jack Lee Vincent K Lam John V Heymach Jianjun Zhang Xiuning Le Source Type: research

Efficacy of targeted therapy in patients with HER2-positive non-small cell lung cancer: A systematic review and meta-analysis
CONCLUSION: HER2-targeted therapy can be considered an acceptable treatment strategy for NSCLC patients with HER2 alterations. In particular, ADC (DS-8201), pyrotinib, and poziotinib demonstrated promising anti-tumour activity in HER2-positive NSCLC.PMID:34820879 | DOI:10.1111/bcp.15155 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - November 25, 2021 Category: Cancer & Oncology Authors: Hong-Xia Wu Kai-Quan Zhuo Ke Wang Source Type: research

4DCT and VMAT for lung patients with irregular breathing
CONCLUSION: For the cases studied tumor motion range and average density was better represented with 4DCT compared with 3DCT, even in the presence of irregular breathing. 4DCT images allowed for delivery of VMAT plans with acceptable dosimetric accuracy. No significant differences were detected between phase and amplitude resorting. In combination with 4D cone beam imaging at treatment, our findings have given us confidence to introduce 4DCT and VMAT for lung radiotherapy patients with irregular breathing.PMID:34816564 | DOI:10.1002/acm2.13453 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - November 24, 2021 Category: Cancer & Oncology Authors: Rhydian Caines Naomi K Sisson Carl G Rowbottom Source Type: research

Predictive molecular markers for the treatment with immune checkpoint inhibitors in colorectal cancer
J Clin Lab Anal. 2021 Nov 24:e24141. doi: 10.1002/jcla.24141. Online ahead of print.ABSTRACTColorectal cancer is one of the most common malignant tumors and, hence, has become one of the most important public health issues in the world. Treatment with immune checkpoint inhibitors (ICIs) successfully improves the survival rate of patients with melanoma, non-small-cell lung cancer, and other malignancies, and its application in metastatic colorectal cancer is being actively explored. However, a few patients develop drug resistance. Predictive molecular markers are important tools to precisely screen patient groups that can b...
Source: Clinical Lung Cancer - November 24, 2021 Category: Cancer & Oncology Authors: Fenqi Du Yanlong Liu Source Type: research

Clinical application of preserving spontaneous breathing non-intubation anesthesia in thoracoscopic surgery for lung cancer under ERAS concept
Asia Pac J Clin Oncol. 2021 Nov 24. doi: 10.1111/ajco.13726. Online ahead of print.ABSTRACTOBJECTIVE: To explore the safety and feasibility of thoracoscopic surgery in patients with lung cancer under non-intubation anesthesia, and to evaluate the advantages of the non-intubation anesthesia compared with intubation anesthesia on enhanced recovery after surgery (ERAS).METHODS: A retrospective cohort study was conducted in which 100 patients who underwent thoracoscopic lung cancer surgery from January 2020 to February 2021 in the Department of Thoracic Surgery of the First Affiliated Hospital of Soochow University were includ...
Source: Clinical Lung Cancer - November 24, 2021 Category: Cancer & Oncology Authors: Longzhou Qi Ke Chen Bin Luo Guocai Mao Liangbin Pan Haitao Huang Jian Li Shaomu Chen Source Type: research

4DCT and VMAT for lung patients with irregular breathing
CONCLUSION: For the cases studied tumor motion range and average density was better represented with 4DCT compared with 3DCT, even in the presence of irregular breathing. 4DCT images allowed for delivery of VMAT plans with acceptable dosimetric accuracy. No significant differences were detected between phase and amplitude resorting. In combination with 4D cone beam imaging at treatment, our findings have given us confidence to introduce 4DCT and VMAT for lung radiotherapy patients with irregular breathing.PMID:34816564 | DOI:10.1002/acm2.13453 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - November 24, 2021 Category: Cancer & Oncology Authors: Rhydian Caines Naomi K Sisson Carl G Rowbottom Source Type: research

Predictive molecular markers for the treatment with immune checkpoint inhibitors in colorectal cancer
J Clin Lab Anal. 2021 Nov 24:e24141. doi: 10.1002/jcla.24141. Online ahead of print.ABSTRACTColorectal cancer is one of the most common malignant tumors and, hence, has become one of the most important public health issues in the world. Treatment with immune checkpoint inhibitors (ICIs) successfully improves the survival rate of patients with melanoma, non-small-cell lung cancer, and other malignancies, and its application in metastatic colorectal cancer is being actively explored. However, a few patients develop drug resistance. Predictive molecular markers are important tools to precisely screen patient groups that can b...
Source: Clinical Lung Cancer - November 24, 2021 Category: Cancer & Oncology Authors: Fenqi Du Yanlong Liu Source Type: research

Clinical application of preserving spontaneous breathing non-intubation anesthesia in thoracoscopic surgery for lung cancer under ERAS concept
Asia Pac J Clin Oncol. 2021 Nov 24. doi: 10.1111/ajco.13726. Online ahead of print.ABSTRACTOBJECTIVE: To explore the safety and feasibility of thoracoscopic surgery in patients with lung cancer under non-intubation anesthesia, and to evaluate the advantages of the non-intubation anesthesia compared with intubation anesthesia on enhanced recovery after surgery (ERAS).METHODS: A retrospective cohort study was conducted in which 100 patients who underwent thoracoscopic lung cancer surgery from January 2020 to February 2021 in the Department of Thoracic Surgery of the First Affiliated Hospital of Soochow University were includ...
Source: Clinical Lung Cancer - November 24, 2021 Category: Cancer & Oncology Authors: Longzhou Qi Ke Chen Bin Luo Guocai Mao Liangbin Pan Haitao Huang Jian Li Shaomu Chen Source Type: research

TMPRSS4 promotes cancer stem-like properties in prostate cancer cells through upregulation of SOX2 by SLUG and TWIST1
CONCLUSIONS: Together, these findings suggest that TMPRSS4 promotes CSC features in prostate cancer through upregulation of the SLUG- and TWIST1-induced stem cell factor SOX2 beyond EMT. Thus, TMPRSS4/SLUG-TWIST1/SOX2 axis may represent a novel mechanism involved in the control of tumor progression.PMID:34809669 | DOI:10.1186/s13046-021-02147-7 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - November 23, 2021 Category: Cancer & Oncology Authors: Yunhee Lee Junghwa Yoon Dongjoon Ko Minyeong Yu Soojin Lee Semi Kim Source Type: research

Clinical Applications of Artificial Intelligence in Positron Emission Tomography of Lung Cancer
PET Clin. 2022 Jan;17(1):77-84. doi: 10.1016/j.cpet.2021.09.001.ABSTRACTThe ability of a computer to perform tasks normally requiring human intelligence or artificial intelligence (AI) is not new. However, until recently, practical applications in medical imaging were limited, especially in the clinic. With advances in theory, microelectronic circuits, and computer architecture as well as our ability to acquire and access large amounts of data, AI is becoming increasingly ubiquitous in medical imaging. Of particular interest to our community, radiomics tries to identify imaging features of specific pathology that can repre...
Source: Clinical Lung Cancer - November 23, 2021 Category: Cancer & Oncology Authors: Katherine A Zukotynski Vincent C Gaudet Carlos F Uribe Katarina Chiam Fran çois Bénard Victor H Gerbaudo Source Type: research

PD-1 iNhibitor and chemotherapy with concurrent IRradiation at VAried tumor sites in advanced Non-small cell lung cAncer: the Prospective Randomized Phase 3 NIRVANA-Lung Trial
This study is a national multicenter 1:1 randomized phase III trial testing in 460 patients, the addition of multisite radiotherapy in advanced NSCLC treated with standard immune checkpoint inhibitors (pembrolizumab)-chemotherapy in first line. The primary objective of the trial is to compare the overall survival between the 2 arms at year 1 of the study. The secondary objective is to compare the progression-free survival and cancer-specific survival at year 1 and 2, as well as to determine quality of life, local and distant control in irradiated and nonirradiated sites at 6 months and year 1.PMID:34810130 | DOI:10.1016/j....
Source: Clinical Lung Cancer - November 23, 2021 Category: Cancer & Oncology Authors: J érôme Doyen Benjamin Besse Matthieu Texier Naima Bonnet Antonin Levy Source Type: research

Circ_0000463 contributes to the progression and glutamine metabolism of non-small-cell lung cancer by targeting miR-924/SLC1A5 signaling
CONCLUSION: Circ_0000463 absence suppressed the malignant behaviors and glutamine metabolism of NSCLC cells through mediating miR-924/SLC1A5 axis.PMID:34811815 | DOI:10.1002/jcla.24116 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - November 23, 2021 Category: Cancer & Oncology Authors: Yunzhong Liu Shujun Wang Songli Pan Qingfeng Yan Yueping Li Ying Zhao Source Type: research

Current status and future perspectives on immunotherapy in neoadjuvant therapy of resectable non-small cell lung cancer
Asia Pac J Clin Oncol. 2021 Nov 23. doi: 10.1111/ajco.13665. Online ahead of print.ABSTRACTResectable non-small cell lung cancer (NSCLC) is defined as stage I-II, and some locally advanced (stage III) tumor. Despite the associated relatively high recurrence rates after surgery, surgical treatment remains the standard treatment for patients with early-stage NSCLC. At present, neoadjuvant therapy is becoming an increasingly popular therapeutic strategy for resectable NSCLC. However, studies have reported that neoadjuvant chemotherapy only slightly improves recurrence rates, making it inadequate for extending patient survival...
Source: Clinical Lung Cancer - November 23, 2021 Category: Cancer & Oncology Authors: Xingyu Liu Huifang Xing Hongyu Liu Jun Chen Source Type: research

Regorafenib outcomes from the population based South Australian Metastatic Colorectal Cancer Registry
CONCLUSION: The survival outcome for those patients from our population-based registry who access regorafenib is in keeping with reports from large, randomized trials. Thus, clinicians can quote local real world data when discussing efficacy and access to regorafenib therapy for mCRC patients.PMID:34811937 | DOI:10.1111/ajco.13672 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - November 23, 2021 Category: Cancer & Oncology Authors: Anas Alawawdeh Timothy Price Christos Karapetis Cynthia Piantadosi Rob Padbury Amitesh Roy Guy Maddern James Moore Scott Carruthers David Roder Amanda R Townsend Source Type: research

Expression and prognostic significance of m6A-related genes in TP53-mutant non-small-cell lung cancer
J Clin Lab Anal. 2021 Nov 23:e24118. doi: 10.1002/jcla.24118. Online ahead of print.ABSTRACTBACKGROUND: TP53 is an important tumor suppressor gene on human 17th chromosome with its mutations more than 60% in tumor cells. Lung cancer is the highest incidence malignancy in men around the world. N-6 methylase (m6A) is an enzyme that plays an important role in mRNA splicing, translation, and stabilization. However, its role in TP53-mutant non-small-cell lung cancer (NSCLC) remains unknown.METHOD: First, we investigated 17 common m6A regulators' prognostic values in NSCLC. Then, after the establishment of risk signature, we exp...
Source: Clinical Lung Cancer - November 23, 2021 Category: Cancer & Oncology Authors: Zhuochen Zhao Junhu Wan Manman Guo Yangxia Wang Zhengwu Yang Fuyou Zhou Zhuofang Li Liang Ming Source Type: research

Efficacy of single-site radiotherapy plus PD-1 inhibitors vs PD-1 inhibitors for oligometastatic non-small cell lung cancer
J Cancer Res Clin Oncol. 2021 Nov 23. doi: 10.1007/s00432-021-03849-3. Online ahead of print.ABSTRACTPURPOSE: Growing numbers of clinical trials test the efficacy of radiotherapy (RT) plus immune checkpoint inhibitors (ICIs), but the number of irradiated sites is not uniform. We aimed to evaluate the efficacy of single-site RT plus immunotherapy in oligometastatic non-small cell lung cancer (NSCLC) with smaller disease burdens and low tumor heterogeneity.METHODS: We retrospectively identified oligometastatic NSCLC (
Source: Clinical Lung Cancer - November 23, 2021 Category: Cancer & Oncology Authors: Peiliang Wang Tianwen Yin Kaikai Zhao Jinming Yu Feifei Teng Source Type: research

TMPRSS4 promotes cancer stem-like properties in prostate cancer cells through upregulation of SOX2 by SLUG and TWIST1
CONCLUSIONS: Together, these findings suggest that TMPRSS4 promotes CSC features in prostate cancer through upregulation of the SLUG- and TWIST1-induced stem cell factor SOX2 beyond EMT. Thus, TMPRSS4/SLUG-TWIST1/SOX2 axis may represent a novel mechanism involved in the control of tumor progression.PMID:34809669 | DOI:10.1186/s13046-021-02147-7 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - November 23, 2021 Category: Cancer & Oncology Authors: Yunhee Lee Junghwa Yoon Dongjoon Ko Minyeong Yu Soojin Lee Semi Kim Source Type: research

Clinical Applications of Artificial Intelligence in Positron Emission Tomography of Lung Cancer
PET Clin. 2022 Jan;17(1):77-84. doi: 10.1016/j.cpet.2021.09.001.ABSTRACTThe ability of a computer to perform tasks normally requiring human intelligence or artificial intelligence (AI) is not new. However, until recently, practical applications in medical imaging were limited, especially in the clinic. With advances in theory, microelectronic circuits, and computer architecture as well as our ability to acquire and access large amounts of data, AI is becoming increasingly ubiquitous in medical imaging. Of particular interest to our community, radiomics tries to identify imaging features of specific pathology that can repre...
Source: Clinical Lung Cancer - November 23, 2021 Category: Cancer & Oncology Authors: Katherine A Zukotynski Vincent C Gaudet Carlos F Uribe Katarina Chiam Fran çois Bénard Victor H Gerbaudo Source Type: research

PD-1 iNhibitor and chemotherapy with concurrent IRradiation at VAried tumor sites in advanced Non-small cell lung cAncer: the Prospective Randomized Phase 3 NIRVANA-Lung Trial
This study is a national multicenter 1:1 randomized phase III trial testing in 460 patients, the addition of multisite radiotherapy in advanced NSCLC treated with standard immune checkpoint inhibitors (pembrolizumab)-chemotherapy in first line. The primary objective of the trial is to compare the overall survival between the 2 arms at year 1 of the study. The secondary objective is to compare the progression-free survival and cancer-specific survival at year 1 and 2, as well as to determine quality of life, local and distant control in irradiated and nonirradiated sites at 6 months and year 1.PMID:34810130 | DOI:10.1016/j....
Source: Clinical Lung Cancer - November 23, 2021 Category: Cancer & Oncology Authors: J érôme Doyen Benjamin Besse Matthieu Texier Naima Bonnet Antonin Levy Source Type: research

Circ_0000463 contributes to the progression and glutamine metabolism of non-small-cell lung cancer by targeting miR-924/SLC1A5 signaling
CONCLUSION: Circ_0000463 absence suppressed the malignant behaviors and glutamine metabolism of NSCLC cells through mediating miR-924/SLC1A5 axis.PMID:34811815 | DOI:10.1002/jcla.24116 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - November 23, 2021 Category: Cancer & Oncology Authors: Yunzhong Liu Shujun Wang Songli Pan Qingfeng Yan Yueping Li Ying Zhao Source Type: research

Current status and future perspectives on immunotherapy in neoadjuvant therapy of resectable non-small cell lung cancer
Asia Pac J Clin Oncol. 2021 Nov 23. doi: 10.1111/ajco.13665. Online ahead of print.ABSTRACTResectable non-small cell lung cancer (NSCLC) is defined as stage I-II, and some locally advanced (stage III) tumor. Despite the associated relatively high recurrence rates after surgery, surgical treatment remains the standard treatment for patients with early-stage NSCLC. At present, neoadjuvant therapy is becoming an increasingly popular therapeutic strategy for resectable NSCLC. However, studies have reported that neoadjuvant chemotherapy only slightly improves recurrence rates, making it inadequate for extending patient survival...
Source: Clinical Lung Cancer - November 23, 2021 Category: Cancer & Oncology Authors: Xingyu Liu Huifang Xing Hongyu Liu Jun Chen Source Type: research

Regorafenib outcomes from the population based South Australian Metastatic Colorectal Cancer Registry
CONCLUSION: The survival outcome for those patients from our population-based registry who access regorafenib is in keeping with reports from large, randomized trials. Thus, clinicians can quote local real world data when discussing efficacy and access to regorafenib therapy for mCRC patients.PMID:34811937 | DOI:10.1111/ajco.13672 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - November 23, 2021 Category: Cancer & Oncology Authors: Anas Alawawdeh Timothy Price Christos Karapetis Cynthia Piantadosi Rob Padbury Amitesh Roy Guy Maddern James Moore Scott Carruthers David Roder Amanda R Townsend Source Type: research

Expression and prognostic significance of m6A-related genes in TP53-mutant non-small-cell lung cancer
J Clin Lab Anal. 2021 Nov 23:e24118. doi: 10.1002/jcla.24118. Online ahead of print.ABSTRACTBACKGROUND: TP53 is an important tumor suppressor gene on human 17th chromosome with its mutations more than 60% in tumor cells. Lung cancer is the highest incidence malignancy in men around the world. N-6 methylase (m6A) is an enzyme that plays an important role in mRNA splicing, translation, and stabilization. However, its role in TP53-mutant non-small-cell lung cancer (NSCLC) remains unknown.METHOD: First, we investigated 17 common m6A regulators' prognostic values in NSCLC. Then, after the establishment of risk signature, we exp...
Source: Clinical Lung Cancer - November 23, 2021 Category: Cancer & Oncology Authors: Zhuochen Zhao Junhu Wan Manman Guo Yangxia Wang Zhengwu Yang Fuyou Zhou Zhuofang Li Liang Ming Source Type: research

A Multicenter, Randomized Phase III Study Comparing Platinum Combination Chemotherapy Plus Pembrolizumab With Platinum Combination Chemotherapy Plus Nivolumab and Ipilimumab for Treatment-Naive Advanced Non-Small Cell Lung Cancer Without Driver Gene Alterations: JCOG2007 (NIPPON Study)
CONCLUSION: If the primary endpoint is met, platinum combination chemotherapy together with nivolumab plus ipilimumab will be established as a new, more effective standard treatment for advanced NSCLC.PMID:34802879 | DOI:10.1016/j.cllc.2021.10.012 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - November 22, 2021 Category: Cancer & Oncology Authors: Yoshimasa Shiraishi Taiki Hakozaki Shogo Nomura Tomoko Kataoka Kentaro Tanaka Satoru Miura Yuta Sekino Masahiko Ando Hidehito Horinouchi Yuichiro Ohe Isamu Okamoto Source Type: research

Acquired MET-DSTN Fusion Mediated Resistance to EGFR-TKIs in Lung Adenocarcinoma and Responded to Crizotinib Plus Gefitinib: A Case Report
Clin Lung Cancer. 2021 Oct 25:S1525-7304(21)00275-8. doi: 10.1016/j.cllc.2021.10.006. Online ahead of print.NO ABSTRACTPMID:34802880 | DOI:10.1016/j.cllc.2021.10.006 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - November 22, 2021 Category: Cancer & Oncology Authors: Yalun Li Ke Wang Panwen Tian Weimin Li Source Type: research

Prediagnostic Serum-25 Hydroxyvitamin D and Mortality Among Bladder Cancer Patients in the Janus Serum Bank Cohort: Answer to a Short Comment [Response to Letter]
Clin Epidemiol. 2021 Nov 8;13:1061-1062. doi: 10.2147/CLEP.S345565. eCollection 2021.NO ABSTRACTPMID:34803404 | PMC:PMC8599866 | DOI:10.2147/CLEP.S345565 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - November 22, 2021 Category: Cancer & Oncology Authors: Bettina K Andreassen Helga H Hektoen Karol Axcrona Hilde Langseth Jo S Stenehjem Trude E Robsahm Source Type: research

Technical Feasibility and Safety of Repeated Computed Tomography-Guided Transthoracic Intratumoral Injection of Gene-Modified Cellular Immunotherapy in Metastatic NSCLC
JTO Clin Res Rep. 2021 Oct 14;2(11):100242. doi: 10.1016/j.jtocrr.2021.100242. eCollection 2021 Nov.ABSTRACTINTRODUCTION: To assess the technical feasibility and safety of repeated percutaneous computed tomography (CT)-guided transthoracic biopsies and intratumoral injections of gene-modified dendritic cells in metastatic NSCLC.METHODS: A total of 15 patients with 15 NSCLC lesions measuring greater than 1.0 cm underwent two cycles of intratumoral biopsies and CCL21 dendritic cell injections separated by 7 days. All needle placements and injections were done under CT guidance. Clinical and imaging follow-up was done approxi...
Source: Clinical Lung Cancer - November 22, 2021 Category: Cancer & Oncology Authors: Puja Shahrouki Jay M Lee Jonathan Barclay Sarah N Khan Scott Genshaft Fereidoun Abtin Steven M Dubinett Aaron Lisberg Sherven Sharma Edward B Garon Robert Suh Source Type: research

Recommended testing algorithms for NTRK gene fusions in pediatric and selected adult cancers: Consensus of a Singapore Task Force
Asia Pac J Clin Oncol. 2021 Nov 21. doi: 10.1111/ajco.13727. Online ahead of print.ABSTRACTThe occurrence of neurotrophic tyrosine receptor kinase (NTRK) gene fusions in a wide range of tumor types presents an attractive opportunity for using a tropomyosin receptor kinase (TRK) inhibitor as cancer therapy. Recent clinical studies have demonstrated highly efficacious outcomes associated with the use of TRK inhibitors, such as larotrectinib and entrectinib in NTRK fusion-bearing cancers, in both adult and pediatric populations. While NTRK gene fusions are commonly found in some uncommon adult and pediatric malignancies, they...
Source: Clinical Lung Cancer - November 22, 2021 Category: Cancer & Oncology Authors: Kiat Hon Tony Lim Hwai Loong Kong Kenneth Tou En Chang Daniel Shao Weng Tan Iain Bee Huat Tan Farid Mohamad Shui Yen Soh Brendan Nghee-Kheem Pang Ross Andrew Soo Su Pin Choo Wen-Son Hsieh LeLe Aung Source Type: research

Robustness of three external beam treatment techniques against inter-fractional positional variations of the metal port in breast tissue expanders
CONCLUSIONS: When IPEs were modeled, dose variability was the largest in tangential 3DCRT, leading to areas of underdosage in the shadow of the port. When PREs were modeled, the target coverage and nearby organs were affected the most in VMAT and helical tomotherapy. In reality, port positional errors result from a combination of IPE and PRE, suggesting that VMAT and tomotherapy are more robust when patient registration errors are minimized, despite the presence of IPE.PMID:34807509 | DOI:10.1002/acm2.13474 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - November 22, 2021 Category: Cancer & Oncology Authors: Keren Mayorov Patricia Lacasse Elsayed Ali Source Type: research

Zebrafish xenograft model for studying mechanism and treatment of non-small cell lung cancer brain metastasis
CONCLUSIONS: We established zebrafish brain metastasis model for studying mechanism and treatment of NSCLC BM. This study provided a useful model for NSCLC brain metastasis that could be used to study the mechanism that drive NSCLC cells to the brain as well as identify potential therapeutic options.PMID:34801071 | DOI:10.1186/s13046-021-02173-5 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - November 21, 2021 Category: Cancer & Oncology Authors: Ruo-Yue Fan Jia-Qi Wu Yu-Yang Liu Xiang-Yu Liu Si-Tong Qian Chong-Yong Li Ping Wei Zhe Song Ming-Fang He Source Type: research

Heterogeneity of BCSCs contributes to the metastatic organotropism of breast cancer
J Exp Clin Cancer Res. 2021 Nov 20;40(1):370. doi: 10.1186/s13046-021-02164-6.ABSTRACTBreast cancer is one of the most-common female malignancies with a high risk of relapse and distant metastasis. The distant metastasis of breast cancer exhibits organotropism, including brain, lung, liver and bone. Breast cancer stem cells (BCSCs) are a small population of breast cancer cells with tumor-initiating ability, which participate in regulating distant metastasis in breast cancer. We investigated the heterogeneity of BCSCs according to biomarker status, epithelial or mesenchymal status and other factors. Based on the classical &...
Source: Clinical Lung Cancer - November 21, 2021 Category: Cancer & Oncology Authors: Cenzhu Wang Kun Xu Runtian Wang Xin Han Jinhai Tang Xiaoxiang Guan Source Type: research

Social Disparities in Lung Cancer Risk and Screening
Thorac Surg Clin. 2022 Feb;32(1):23-31. doi: 10.1016/j.thorsurg.2021.09.011.ABSTRACTSignificant disparities exist in lung cancer incidence and screening. Geographic, racial, gender, and socioeconomic disparities affect lung cancer incidence. As the leading cause of lung cancer, smoking varies among different racioethnic groups, genders, and socioeconomic statuses. In addition, environmental pollutants, such as radon, industrial toxins, and air pollution, are significant risk factors for lung cancer development that is disproportionately seen in working-class communities, as well as underserved and disabled populations. Lun...
Source: Clinical Lung Cancer - November 21, 2021 Category: Cancer & Oncology Authors: Vignesh Raman Valeda Yong Cherie P Erkmen Betty C Tong Source Type: research

Social Disparities in Lung Cancer
Thorac Surg Clin. 2022 Feb;32(1):33-42. doi: 10.1016/j.thorsurg.2021.09.009.ABSTRACTSocial disparities in lung cancer diagnosis, treatment, and survival have been studied using national databases, statewide registries, and institution-level data. Some disparities emerge consistently, such as lower adherence to treatment guidelines and worse survival by race and socioeconomic status, whereas other disparities are less well studied. A critical appraisal of current data is essential to increasing equity in lung cancer care.PMID:34801193 | DOI:10.1016/j.thorsurg.2021.09.009 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - November 21, 2021 Category: Cancer & Oncology Authors: Irmina Elliott Cayo Gonzalez Leah Backhus Natalie Lui Source Type: research

Social Disparities in Thoracic Surgery Database Research: Implications and Impact
Thorac Surg Clin. 2022 Feb;32(1):83-90. doi: 10.1016/j.thorsurg.2021.09.007.ABSTRACTA complex relationship exists between health care disparities and large databases among the thoracic surgical patient population. Using the example of thoracic malignancies, the ability of investigations leveraging large databases and novel analytical approaches to highlight disparate access to care and discordant outcomes following treatment is illustrated. Large, widely used databases may not be representative of the thoracic surgical patient population as a whole, and caution must be used when interpreting and generalizing results gleane...
Source: Clinical Lung Cancer - November 21, 2021 Category: Cancer & Oncology Authors: Kyle G Mitchell Ian C Bostock Mara B Antonoff Source Type: research

The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer
CONCLUSION: A minority of NSCLC samples with EGFR mutations had HER2 alterations. In patients with both mutations, exon 21 mutations for EGFR and exon 8 mutations for HER2 were common. It will be critical to continue to accumulate valuable clinical data for further real-world outcomes analysis.PMID:34801409 | DOI:10.1016/j.cllc.2021.08.012 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - November 21, 2021 Category: Cancer & Oncology Authors: Misako Nagasaka Vijendra Singh Yasmine Baca Ammar Sukari Chul Kim Hirva Mamdani Alexander I Spira Dipesh Uprety Gerold Bepler Edward S Kim Luis E Raez Sachin Gopalkrishna Pai Chukwuemeka Ikpeazu Matthew Oberley Rebecca Feldman Joanne Xiu W Michael Korn An Source Type: research

Zebrafish xenograft model for studying mechanism and treatment of non-small cell lung cancer brain metastasis
CONCLUSIONS: We established zebrafish brain metastasis model for studying mechanism and treatment of NSCLC BM. This study provided a useful model for NSCLC brain metastasis that could be used to study the mechanism that drive NSCLC cells to the brain as well as identify potential therapeutic options.PMID:34801071 | DOI:10.1186/s13046-021-02173-5 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - November 21, 2021 Category: Cancer & Oncology Authors: Ruo-Yue Fan Jia-Qi Wu Yu-Yang Liu Xiang-Yu Liu Si-Tong Qian Chong-Yong Li Ping Wei Zhe Song Ming-Fang He Source Type: research

Heterogeneity of BCSCs contributes to the metastatic organotropism of breast cancer
J Exp Clin Cancer Res. 2021 Nov 20;40(1):370. doi: 10.1186/s13046-021-02164-6.ABSTRACTBreast cancer is one of the most-common female malignancies with a high risk of relapse and distant metastasis. The distant metastasis of breast cancer exhibits organotropism, including brain, lung, liver and bone. Breast cancer stem cells (BCSCs) are a small population of breast cancer cells with tumor-initiating ability, which participate in regulating distant metastasis in breast cancer. We investigated the heterogeneity of BCSCs according to biomarker status, epithelial or mesenchymal status and other factors. Based on the classical &...
Source: Clinical Lung Cancer - November 21, 2021 Category: Cancer & Oncology Authors: Cenzhu Wang Kun Xu Runtian Wang Xin Han Jinhai Tang Xiaoxiang Guan Source Type: research

Social Disparities in Lung Cancer Risk and Screening
Thorac Surg Clin. 2022 Feb;32(1):23-31. doi: 10.1016/j.thorsurg.2021.09.011.ABSTRACTSignificant disparities exist in lung cancer incidence and screening. Geographic, racial, gender, and socioeconomic disparities affect lung cancer incidence. As the leading cause of lung cancer, smoking varies among different racioethnic groups, genders, and socioeconomic statuses. In addition, environmental pollutants, such as radon, industrial toxins, and air pollution, are significant risk factors for lung cancer development that is disproportionately seen in working-class communities, as well as underserved and disabled populations. Lun...
Source: Clinical Lung Cancer - November 21, 2021 Category: Cancer & Oncology Authors: Vignesh Raman Valeda Yong Cherie P Erkmen Betty C Tong Source Type: research

Social Disparities in Lung Cancer
Thorac Surg Clin. 2022 Feb;32(1):33-42. doi: 10.1016/j.thorsurg.2021.09.009.ABSTRACTSocial disparities in lung cancer diagnosis, treatment, and survival have been studied using national databases, statewide registries, and institution-level data. Some disparities emerge consistently, such as lower adherence to treatment guidelines and worse survival by race and socioeconomic status, whereas other disparities are less well studied. A critical appraisal of current data is essential to increasing equity in lung cancer care.PMID:34801193 | DOI:10.1016/j.thorsurg.2021.09.009 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - November 21, 2021 Category: Cancer & Oncology Authors: Irmina Elliott Cayo Gonzalez Leah Backhus Natalie Lui Source Type: research

Social Disparities in Thoracic Surgery Database Research: Implications and Impact
Thorac Surg Clin. 2022 Feb;32(1):83-90. doi: 10.1016/j.thorsurg.2021.09.007.ABSTRACTA complex relationship exists between health care disparities and large databases among the thoracic surgical patient population. Using the example of thoracic malignancies, the ability of investigations leveraging large databases and novel analytical approaches to highlight disparate access to care and discordant outcomes following treatment is illustrated. Large, widely used databases may not be representative of the thoracic surgical patient population as a whole, and caution must be used when interpreting and generalizing results gleane...
Source: Clinical Lung Cancer - November 21, 2021 Category: Cancer & Oncology Authors: Kyle G Mitchell Ian C Bostock Mara B Antonoff Source Type: research

The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer
CONCLUSION: A minority of NSCLC samples with EGFR mutations had HER2 alterations. In patients with both mutations, exon 21 mutations for EGFR and exon 8 mutations for HER2 were common. It will be critical to continue to accumulate valuable clinical data for further real-world outcomes analysis.PMID:34801409 | DOI:10.1016/j.cllc.2021.08.012 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - November 21, 2021 Category: Cancer & Oncology Authors: Misako Nagasaka Vijendra Singh Yasmine Baca Ammar Sukari Chul Kim Hirva Mamdani Alexander I Spira Dipesh Uprety Gerold Bepler Edward S Kim Luis E Raez Sachin Gopalkrishna Pai Chukwuemeka Ikpeazu Matthew Oberley Rebecca Feldman Joanne Xiu W Michael Korn An Source Type: research

Meta-analysis of Lobectomy and Sublobar Resection for Stage I Non-small Cell Lung Cancer With Spread Through Air Spaces
Clin Lung Cancer. 2021 Oct 23:S1525-7304(21)00268-0. doi: 10.1016/j.cllc.2021.10.004. Online ahead of print.ABSTRACTSurgery is the preferred treatment for early-stage non-small cell lung cancer (NSCLC). Numerous studies have shown that spread through air spaces (STAS) can predict the survival of patients with stage I NSCLC. However, for stage I NSCLC, it is not known whether sublobar resection or lobectomy should be performed if STAS is present. In the present study, we compared the survival outcomes of patients with STAS who underwent lobectomy versus those who underwent sublobar resection. A search was performed on the P...
Source: Clinical Lung Cancer - November 20, 2021 Category: Cancer & Oncology Authors: Jialong Li Yan Wang Jue Li Shangqi Cao Guowei Che Source Type: research

A novel model based on liquid-liquid phase separation-Related genes correlates immune microenvironment profiles and predicts prognosis of lung squamous cell carcinoma
J Clin Lab Anal. 2021 Nov 19:e24135. doi: 10.1002/jcla.24135. Online ahead of print.ABSTRACTOBJECTIVE: The aim of the study was to construct and validate a robust prognostic model based on liquid-liquid phase separation (LLPS)-related genes in lung squamous cell carcinoma (LUSC).METHODS: The Cancer Genome Atlas dataset was used as the discovery set to identify the LLPS-related differentially expressed genes (DEGs) between LUSC and normal tissue. These DEGs were screened by the LASSO Cox regression analysis to identify the genes with nonzero coefficient, which were next included in the multivariate Cox regression analysis t...
Source: Clinical Lung Cancer - November 20, 2021 Category: Cancer & Oncology Authors: Lingdun Zhuge Kun Zhang Zeliang Zhang Wentao Guo Yang Li Qi Bao Source Type: research

Lung Cancer-Related Dyspnea: The Effects of a Handheld Fan on Management of Symptoms
Clin J Oncol Nurs. 2021 Dec 1;25(6):655-661. doi: 10.1188/21.CJON.655-661.ABSTRACTBACKGROUND: The application of a handheld fan may reduce patients' shortness of breath and increase their activity tolerance by enabling cooling and air flow into the second and third branches of the trigeminal nerve.OBJECTIVES: The aim of the study was to assess the effects of directing a handheld fan toward the face in the management of lung cancer-related dyspnea.METHODS: Using a randomized controlled experimental design, 96 inpatients with lung cancer were evaluated, with the experimental group (n = 49) using a handheld fan to manage dysp...
Source: Clinical Lung Cancer - November 20, 2021 Category: Cancer & Oncology Authors: Vildan Kocatepe Gulbeyaz Can Özlem Oruç Source Type: research

Dyspnea: Common Side Effect
Clin J Oncol Nurs. 2021 Dec 1;25(6):10-12. doi: 10.1188/21.CJON.S2.10-12.ABSTRACTFor dyspnea, standards of care are based on emerging evidence-based practice. Dyspnea, or shortness of breath, is a subjective experience of breathing discomfort marked by distinct sensations of varying intensity. Resulting from interactions among physiologic, psychological, social, and environmental factors, dyspnea may lead to secondary physiologic and behavioral responses. Dyspnea can be caused by cardiac and pulmonary disease (e.g., congestive heart failure, acute coronary syndrome, pneumonia, chronic obstructive pulmonary disease...
Source: Clinical Lung Cancer - November 20, 2021 Category: Cancer & Oncology Source Type: research

Meta-analysis of Lobectomy and Sublobar Resection for Stage I Non-small Cell Lung Cancer With Spread Through Air Spaces
Clin Lung Cancer. 2021 Oct 23:S1525-7304(21)00268-0. doi: 10.1016/j.cllc.2021.10.004. Online ahead of print.ABSTRACTSurgery is the preferred treatment for early-stage non-small cell lung cancer (NSCLC). Numerous studies have shown that spread through air spaces (STAS) can predict the survival of patients with stage I NSCLC. However, for stage I NSCLC, it is not known whether sublobar resection or lobectomy should be performed if STAS is present. In the present study, we compared the survival outcomes of patients with STAS who underwent lobectomy versus those who underwent sublobar resection. A search was performed on the P...
Source: Clinical Lung Cancer - November 20, 2021 Category: Cancer & Oncology Authors: Jialong Li Yan Wang Jue Li Shangqi Cao Guowei Che Source Type: research